Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP,General Counsel, Secretary | January 06, 2024 | January 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date January 06, 2024 · Filed January 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,901 |
Ending reported balance
After 2024-01-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-06 · Exercise / conversion · Acquired 1,634 · Balance 47,491 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Row 2 · 2024-01-08 · Sale · Disposed 590 · Balance 46,901 F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.6641 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-06 · Exercise / conversion · Disposed 1,634 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.6641 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2019 Filed Dec 13, 2019 22:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001209191-19-060475 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,500 Underlying: Common Stock · 17,500 shares Expires 2028-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the 140,000 shares originally subject to the stock option vested and became exercisable on July 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 22:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 17,500 | $45.06 | $788,576.25 |
DisclosureSEC source: 0001209191-19-060475 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.215, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 22:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 17,500 | $17.58 | $307,650.00 |
DisclosureSEC source: 0001209191-19-060475 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 452 shares of the Issuer's common stock acquired by the reporting person on May 15, 2019 and 57 shares of the Issuer's common stock acquired by the reporting person on November 15, 2019 pursuant to an employee stock purchase program. Read SEC document |
| April 29, 2019 Filed May 1, 2019 21:58 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 12,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026845 · doc4.xml · derivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,019 Underlying: Common Stock · 12,019 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. Read SEC document |
| April 29, 2019 Filed May 1, 2019 21:58 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 42,173 | $0.00 Strike: $25.12 | $0.00 |
DisclosureSEC source: 0001209191-19-026845 · doc4.xml · derivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,173 Underlying: Common Stock · 42,173 shares Expires 2029-04-29 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 23:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001415889-18-001160 · form4-07202018_040702.xml · derivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2028-07-17 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on July 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.